Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable
Go back to Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 17.26 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.26 | 52 Week High | $63.73 | |||
| Open | $17.26 | 52 Week Low | $8.00 | |||
| Day High | $17.26 | P/E | N/A | |||
| Day Low | $17.26 | EPS | $-5.69 | |||
| Volume | 801 | |||||
